11/12
08:07 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "peer perform" rating reaffirmed by analysts at Wolfe Research.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "peer perform" rating reaffirmed by analysts at Wolfe Research.
11/12
08:07 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "peer perform" rating reaffirmed by analysts at Wolfe Research.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "peer perform" rating reaffirmed by analysts at Wolfe Research.
11/12
06:59 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/12
06:59 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/12
06:43 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at Evercore ISI to a "hold" rating.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at Evercore ISI to a "hold" rating.
11/12
06:43 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at Evercore ISI to a "hold" rating.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was upgraded by analysts at Evercore ISI to a "hold" rating.
11/11
05:32 pm
ntla
Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
Medium
Report
Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
11/11
05:32 pm
ntla
Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
Medium
Report
Intellia Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
11/11
05:12 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/11
04:50 am
ntla
Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
Medium
Report
Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
11/11
04:50 am
ntla
Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
Medium
Report
Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
11/7
06:09 pm
ntla
Rating for NTLA
Low
Report
Rating for NTLA
11/7
02:08 pm
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/7
02:08 pm
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/7
01:55 pm
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/7
01:55 pm
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/7
10:27 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/7
10:27 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/7
10:07 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/7
10:07 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/7
08:07 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $5.00 price target on the stock, down previously from $12.00.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) had its "underweight" rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $5.00 price target on the stock, down previously from $12.00.
11/7
07:13 am
ntla
Rating for NTLA
Medium
Report
Rating for NTLA
11/7
05:14 am
ntla
Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan
Low
Report
Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan
10/29
08:01 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.
10/29
08:01 am
ntla
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.
Medium
Report
Intellia Therapeutics (NASDAQ:NTLA) was downgraded by analysts at Royal Bank Of Canada from a "moderate buy" rating to a "hold" rating.